A Competitive Study of Efficacy of Platelet Rich Plasma With Intralesional Triamcinolone in Patients with Alopecia Areata

Abstract

Background: Alopecia areata is a chronic, non-scarring alopecia that involves the scalp and/or body. Corticosteroids are the most popular drugs for their treatment. Aim: To Conduct a Competitive Study of the Efficacy of Platelet-Rich Plasma With Intralesional Triamcinolone in Patients With Alopecia Areata. Methods: A prospective, randomized, controlled clinical trial was conducted at a tertiary care hospital. Participants (n = 100) aged 20–60 years with alopecia areata were randomized into PRP and intralesional TA groups. Primary outcomes included hair regrowth assessed through standardized photographs and the Severity of Alopecia Tool (SALT) score at baseline, post-third treatment session, and 6-month follow-up. Secondary outcomes comprised response rates, safety profiles, treatment response duration, and relapse rates. Statistical analysis employed appropriate tests.

Results: Participants' baseline characteristics were comparable between groups. PRP demonstrated significantly higher hair regrowth rates at post-third session (52% vs. 44%) and 6-month follow-up (70% vs. 50%). Response rates were notably greater in the PRP group (84% vs. 66%). Safety profiles were similar. PRP treatment showed a longer treatment response duration (12.3 vs. 9.9 months) and comparable relapse rates (15% vs. 23.3%). Conclusion: This study highlights the superior efficacy of PRP over intralesional TA in alopecia areata treatment. PRP exhibited higher hair regrowth and response rates, longer treatment response duration, and comparable safety and relapse rates. PRP presents as a promising therapeutic option for managing alopecia areata.